

Article

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants

Farah A. Meah¹, Linda A. DiMeglio^{2,3}, Carla J. Greenbaum⁴, Janice S. Blum⁵, Jay M. Sosenko^{6,7}, Alberto Pugliese^{7,8}, Susan Geyer⁹, Ping Xu⁹, Carmella Evans-Molina^{1,3} for the Type 1 Diabetes TrialNet Study Group

¹Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

²Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA

³Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA

⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, USA

⁵Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA

⁶Department of Medicine, Leonard Miller School of Medicine, University of Miami, Miami, FL, USA

⁷Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL, USA

⁸Department of Microbiology and Immunology, Leonard Miller School of Medicine, University of Miami, Miami, FL, USA

⁹Health Informatics Institute, University of South Florida, Tampa, FL, USA

Complete listing of Type 1 Diabetes TrialNet Study Group members is included in the electronic supplementary material (ESM)

Corresponding author: C. Evans-Molina, Indiana University School of Medicine, 635 Barnhill Drive MS 2031A, Indianapolis, IN, USA
email cevansmo@iu.edu

Received: 21 October 2015 / Accepted: 24 February 2016

This is the author's manuscript of the article published in final edited form as:

Meah, F. A., DiMeglio, L. A., Greenbaum, C. J., Blum, J. S., Sosenko, J. M., Pugliese, A., ... Type 1 Diabetes TrialNet Study Group. (2016). The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. *Diabetologia*, 59(6), 1186–1195. <http://doi.org/10.1007/s00125-016-3924-5>

ABSTRACT

Aims/hypothesis The incidence of type 1 diabetes is increasing at a rate of 3-5% per year. Genetics cannot fully account for this trend, suggesting an influence of environmental factors. The accelerator hypothesis proposes an effect of metabolic factors on type 1 diabetes risk. To test this in the TrialNet Pathway to Prevention (PTP) cohort, we analysed the influence of BMI, weight status and insulin resistance on progression from single to multiple islet autoantibodies (Aab) and progression from normoglycaemia to diabetes.

Methods HOMA1-IR was used to estimate insulin resistance in Aab-positive PTP participants. Cox proportional hazards models were used to evaluate the effects of BMI, BMI percentile (BMI%), weight status and HOMA1-IR on the progression of autoimmunity or the development of diabetes.

Results Data from 1,310 single and 1,897 multiple Aab-positive PTP participants were included. We found no significant relationships between BMI, BMI%, weight status or HOMA1-IR and the progression from one to multiple Aabs. Similarly, among all Aab-positive participants, no significant relationships were found between BMI, weight status or HOMA1-IR and progression to diabetes. Diabetes risk was modestly increased with increasing BMI% among the entire cohort, in obese participants 13-20 years of age, and with increasing HOMA1-IR in adult Aab-positive participants.

Conclusions/interpretation Analysis of the accelerator hypothesis in the TrialNet PTP cohort does not suggest a broad influence of metabolic variables on diabetes risk. Efforts to identify other potentially modifiable environmental factors should continue.

Keywords: Accelerator hypothesis, BMI, Diabetes in childhood, HOMA1-IR, Insulin sensitivity and resistance, Pancreatic autoantibodies, Pathway to Prevention, Prediction and prevention of type 1 diabetes, TrialNet, Type 1 diabetes

Abbreviations

Aab	Autoantibodies
BMI%	BMI percentile
CDC	Centers for Disease Control and Prevention
DPT-1	Diabetes Prevention Trial of Type 1 Diabetes
GAD65	Glutamic acid decarboxylase 65
IA-2/ICA512	Islet-antigen 2
IQR	Interquartile range
PTP	Pathway to Prevention
ZNT8	Zinc transporter 8

Introduction

Type 1 diabetes is a heterogeneous disorder in which a primary or secondary islet insult renders the beta cell antigenic, leading to T-lymphocyte infiltration and production of pro-inflammatory cytokines such as IL-1 β , TNF α and IFN γ . Over the past 30 years, there has been a global and largely unexplained increase in the incidence of type 1 diabetes, especially among younger populations [1, 2]. Between 1989-2003, the EuroDIAB study documented an annual increase in incidence of 5.4%, 4.3% and 2.9%

among children aged 0-4 years, 5-9 years and 10-14 years, respectively [3], while the SEARCH for Diabetes in Youth Study demonstrated a similar increase of 2.6% among American children from 2002-2009 [4]. High-risk *HLA* Class II alleles including *HLA-DR3* and 4 and *DQ2* and 8 increase the risk of type 1 diabetes [5], but the prevalence of these high-risk *HLA* alleles has remained largely stable [6]. Thus, inheritance alone is not likely to account for the rising prevalence of type 1 diabetes, suggesting roles for nongenetic and/or environmental factors.

Environmental influence has been well illustrated by twin studies [7] and reports showing that first-generation children of immigrant parents from regions with a low prevalence of type 1 diabetes experience a risk most similar to that in their new country [8]. Commonly implicated environmental factors include decreased rates of infection due to antibiotics and vaccination (the hygiene hypothesis) [9], viral infections [10], dietary factors and changes in the gut microbiome [11], decreased intake and endogenous synthesis of vitamin D [12], seasonality [13] and exposure to endocrine disrupting chemicals [14].

The accelerator or overload hypothesis is another highly favoured explanation and postulates that chronically increased beta cell secretory demand, occurring as a result of overnutrition, obesity and insulin resistance, may lead to activation of intrinsic beta cell stress pathways that either trigger autoimmunity through formation of neoantigens or act independently to accelerate autoimmune-mediated beta cell death [15]. Although weight loss is typically seen at the time of diabetes diagnosis, weight gain

in early life is suggested to be a risk factor both for the development of diabetes as well as for disease presentation at a younger age [16-19]. Moreover, rates of obesity have increased in children. For example, obesity amongst US children more than doubled in some age groups from 1976-1980 to 2009-2010 [20].

Data from the Diabetes Prevention Trial of Type 1 Diabetes (DPT-1), which served as the precursor to the Type 1 Diabetes TrialNet study, revealed a modest impact of metabolic variables on diabetes risk [21, 22]. However, a DPT-1 Risk Score, which includes BMI, has proven to be predictive of progression to diabetes [23-25]. In another analysis, data from over 9,000 German and Austrian children between the years 1990-2003 revealed higher BMI and weight in those diagnosed with diabetes than those in the control reference population [17].

Given this background, the goal of this study was to test the accelerator hypothesis within a contemporary international and mixed-age cohort at increased genetic risk of diabetes. Type 1 Diabetes TrialNet is an ongoing clinical trial with centres located in the USA, Canada, the UK, Germany, Italy, Australia and New Zealand. In the TrialNet Pathway to Prevention (PTP) cohort, blood relatives of individuals with type 1 diabetes are screened for the presence of pancreatic islet autoantibodies (Aabs). Those positive for at least one Aab are then followed up longitudinally for the development of additional islet Aabs, dysglycaemia and diabetes. By use of data derived from the TrialNet PTP cohort, we tested whether BMI, obesity or overweight status and/or insulin resistance as measured by HOMA1-IR were related to progression of autoimmunity (as

measured by the conversion from single to multiple Aab status) or ultimately to the progression to type 1 diabetes.

Methods

Participants and follow-up Details of the enrolment criteria for entry into the TrialNet PTP cohort, which began in 2001, have been described previously [26]. In brief, nondiabetic first-degree relatives (ages 1-45 years) and second or third-degree relatives (ages 1-20 years) of individuals with type 1 diabetes were screened for the presence of pancreatic islet Aabs in a stepwise fashion. Participants were tested first for the presence of GAD65 (glutamic acid decarboxylase 65), insulin, or IA-2/ICA512 (islet-antigen 2) Aabs, followed by measurement of islet cell Aabs (ICA) or zinc transporter 8 (ZnT8) Aabs if any one initial test was positive [27]. Measurement of ZnT8 was initiated in 2004 [28], and was consistently measured in the PTP cohort starting in 2012. Confirmed Aab positive (Aab+) individuals were invited to participate in longitudinal observation with either semi-annual or annual monitoring. The strategy for monitoring included measurement of height and weight, and performance of a standard protocol OGTT [29].

A total of 134,937 eligible individuals were screened from 2001 through June 30, 2014 (electronic supplementary material [ESM] Fig. 1). A total of 2,299 individuals were confirmed on repeat testing to be single Aab+ (GAD65, insulin or IA-2/ICA512), while a total of 2,960 individuals were identified to be multiple Aab+. Analyses presented here

focus on those who had at least one monitoring visit (1,310 single Aab+ and 1,897 multiple Aab+ individuals). Participants who later entered prevention trials were censored at the time of initial enrolment into the prevention trial. All participants provided written informed consent prior to commencement of data collection. The study was approved by the ethical boards of all participating institutions and was conducted according to standards established by the Declaration of Helsinki.

Laboratory analyses Aab status was assessed using procedures outlined by the Diabetes Antibody Standardization Program and described in detail in previous publications [30]. Glucose was measured using the glucose oxidase method [31]. Insulin was initially measured by radioimmunoassay [32]; however, this was transitioned to a TOSOH AIA (Automated Immunoassay) (San Francisco, CA, USA) in 2009-2010. HOMA1-IR was calculated as described previously using values obtained from the first OGTT performed during the initial monitoring visit [21]. BMI was calculated for each participant using data from the first monitoring visit. For children and adolescents ≤ 19 years of age, BMI z scores (SDs) were calculated using the Centers for Disease Control and Prevention (CDC) SAS program for the 2000 CDC growth charts (www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm); z scores were then used to calculate BMI percentile values using the lambda-mu-sigma (LMS) method as previously described [33]. BMI percentile values for age 20 years were applied to all individuals ≥ 20 years of age. BMI data was missing for 102 (7.8%) of single Aab+

participants and 201 (10.6%) of participants with multiple Aabs. BMI, BMI percentile (BMI%) and HOMA1-IR were defined as continuous variables, whereas BMI/BMI% values were also analysed as categorical variables. BMI category divisions included underweight (BMI <18.5 kg/m² and/or BMI% <5%), normal (BMI ≥ 18.5 kg/m² and < 25 kg/m² and/or BMI percentile ≥ 5% and < 85%), overweight (BMI ≥ 25 kg/m² and < 30 kg/m² and/or BMI percentile ≥ 85% and < 95%) and obese (BMI ≥ 30 kg/m² and/or BMI percentile ≥95%). Diabetes was diagnosed according to American Diabetes Association criteria (confirmed fasting plasma glucose ≥ 7.0 mmol/L, random glucose ≥ 11.1 mmol/L, or HbA_{1c} ≥ 6.5% [48 mmol/mol]) [34].

Statistical methods Categorical variables were compared among groups by Pearson's χ^2 tests or Fisher Exact tests when cell sizes were insufficient. Continuous variables were summarised either by mean \pm SD or median and interquartile range (IQR). Two-sample *t* tests were used to compare the difference of means for these variables between groups. The association of HOMA1-IR, BMI, BMI percentile and time to progression from single to multiple Aab conversion or time to progression to a clinical diagnosis of type 1 diabetes was adjusted for potential confounders using the multivariate Cox proportional hazards model. Assumptions for proportionality of hazards were tested for in these models [35], and age at the initial screen, sex, *HLA* risk, relationship to proband, and race were adjusted for in the model. Age groups were divided into three groups: <13 vs 13-20 vs >20 years old. Interactions between

metabolic variables and age groups were also assessed using first-order interaction terms in the Cox models as well as in stratified analyses based on age groups. All tests of significance were two-sided, where p values < 0.05 were considered to be statistically significant. Statistical analyses were performed with SAS Version 9.2 (Cary, NC, USA).

Results

Anthropometric measurements and metabolic data were collected on PTP participants confirmed to have a single Aab (n=1,310) and those with multiple Aabs (n=1,897) and compared between groups. Participants in both the single and multiple Aab+ groups were predominantly white (82.6% and 86.7%, respectively), non-Hispanic (80.1% and 85.5%, respectively) and first-degree relatives of probands. There was a significantly higher percentage of females in the single Aab+ cohort (60.8%) vs the multiple Aab+ cohort (49.5%). *HLA DR3* or *DR4* was present in 66.9% of single Aab+ and 71.9% of multiple Aab+ individuals (Table 1).

Individuals confirmed as single Aab+ were older at initial screening than multiple Aab+ participants (p<0.001). Of the single Aab+ group, 5.2% (n=69) of participants were underweight, 46.6% (n=611) were categorised as normal weight, 21.2% (n=278) were overweight and 19.1% (n=250) were obese. Of the multiple Aab+ group, 6.9% (n=131) were underweight, 53.8% (n=1020) were normal weight, 14.9% (n=282) were overweight and 13.9% (n=263) were obese. Single Aab+ individuals also had higher HOMA1-IR values than those with multiple Aabs (p=0.001; Table 1).

BMI/BMI percentiles were next analysed as continuous variables and participants were also stratified by weight category as outlined in the Methods. Characteristics of obese and nonobese (underweight, normal weight and overweight) PTP participants are shown in Table 2. Consistent with relationships shown in Table 1, a higher percentage of obese individuals were single Aab+ compared with nonobese individuals (48.7% vs 40.1%, respectively; $p=0.0004$). Obese participants tended to be older at initial screening than nonobese participants (median age: 28.2 vs 11.9 years, respectively; $p<0.001$). However, overall age ranges were overlapping for obese and nonobese participants: 1.30–45.99 years vs 1.01–46.59 years, respectively (ESM Table 1).

Among the 1,310 confirmed single Aab+ PTP participants who had at least one monitoring visit, 288 (22.0%) individuals progressed to multiple Aab+ status during follow-up. The median follow-up time of single Aab+ individuals was 2.5 years (IQR 1.32-4.38 years). Univariate analysis confirmed an increased risk of progression to multiple positive Aabs or diabetes in younger, male individuals [36]. Interestingly, univariate analysis also suggested a protective effect of overweight status on the risk of progression to multiple Aabs (HR 0.64, 95% CI 0.46, 0.88; $p=0.01$). Similarly, higher BMI and BMI percentiles were also associated with a moderately decreased risk of progression to multiple Aabs ($p<0.01$). No other significant associations were seen between metabolic variables and progression to multiple Aabs in univariate analysis (Table 3).

Cox proportional hazards models were used next to evaluate the influence of HOMA1-IR, BMI, BMI percentile and BMI category on the progression from single to multiple Aabs after adjusting for age, sex, *HLA* risk, relationship to proband and race (Table 4). In the adjusted analysis, the protective effect of BMI or overweight status did not persist, and no statistically significant relationships were revealed between BMI ($p=0.73$), BMI percentile ($p=0.27$), overweight ($p=0.34$) or obese ($p=0.96$) status, or HOMA1-IR ($p=0.47$) and risk of progression from single to multiple Aab status. Similarly, no relationship was seen between underweight status and this endpoint ($p=0.70$).

Among 3,207 single or multiple Aab+ PTP participants, 647 (20.2%) individuals progressed to diabetes. Type 1 diabetes developed in 579/1,897 (30.5%) individuals with multiple Aabs and only 68/1,310 (5.2%) individuals with a confirmed single Aab over the median follow-up time of 2.31 years (IQR 0.97-4.20 years). Individuals positive for *HLA DR3* and *DR4* demonstrated the expected increase in risk of progression to diabetes (Table 3). Univariate analysis suggested an increased risk of underweight status (HR 1.90, 95% CI 1.46, 2.47), but again a protective effect of obese status on the risk of progression to diabetes as an outcome (HR 0.77, 95% CI 0.60, 0.98; $p=0.032$). Higher BMI was also found to be associated with a decreased risk of progression to diabetes in univariate analysis (HR 0.93, 95% CI 0.92,0.95; $p<0.001$). However, after adjusting for age, sex, race, relationship to proband and *HLA* risk, no significant associations between BMI ($p=0.29$), underweight ($p=0.96$), overweight ($p=0.08$) or obese status ($p=0.10$), or HOMA1-IR ($p=0.56$) and progression to diabetes in single and

multiple Aab+ participants were revealed (Table 4). This analysis revealed a modestly increased risk of diabetes with increasing BMI% (HR 1.004, 1.00-1.01; $p=0.04$). Furthermore, there was a significant interaction between obesity and age group in relation to time to type 1 diabetes ($p=0.04$); i.e. there was a differential impact of obesity on time to type 1 diabetes between age groups. Specifically, obesity significantly increased the risk of type 1 diabetes in individuals who were 13-20 years old (HR=2.06, $p=0.045$; Table 5).

We next stratified participants by Aab status, and Cox proportional hazards models were used to analyse progression to type 1 diabetes as an outcome. Again, we found no associations between BMI, BMI percentile, obesity or overweight status, or HOMA1-IR and time to progression to diabetes when single Aab+ individuals and multiple Aab+ individuals were analysed separately (Table 5).

Finally, Aab+ individuals were stratified by age, such that age at initial screening was categorised into three groups: <13 vs 13 to 20 vs over 20 years of age. Subgroup analysis revealed that obese participants aged 13-20 years displayed a significantly increased risk of progression to diabetes compared with age-matched normal-weight participants (HR 2.06, 95% CI 1.02, 4.19; $p=0.045$; Table 5). Furthermore, increasing HOMA1-IR was associated with a moderate risk of progression to diabetes in adult Aab+ individuals who were >20 years of age (HR 1.17, 95% CI 1.05, 1.31; $p=0.004$). We further evaluated changes in HOMA-IR levels from baseline to the last assessment performed before diabetes diagnosis. Interestingly, there was a significantly larger

change in HOMA-IR values from baseline among those who developed type 1 diabetes compared to those who remained diabetes free in the overall cohort (0.23 ± 1.28 vs 0.03 ± 1.36 ; $p < 0.001$). When only individuals >20 years of age were considered, the change in HOMA-IR for those who developed diabetes was 0.76 ± 2.39 vs a change of 0.02 ± 0.96 in those who remained diabetes free; $p < 0.001$).

Discussion

Here, we tested whether metabolic variables were related to progression from one to multiple Aabs or ultimately to type 1 diabetes as an outcome within the TrialNet PTP cohort. Our analysis failed to reveal a significant relationship between BMI, BMI percentile, weight status or insulin resistance and conversion from one to multiple islet Aabs. Similar findings were seen in the analysis between metabolic factors and progression to diabetes. The only exception was that increasing BMI% was associated with an increased risk of progression to type 1 diabetes in single and multiple Aab+ participants (Table 3). However, this effect was quite modest (HR 1.004, 95% CI 1.00, 1.01; $p = 0.04$). Further analysis following stratification by age revealed that obesity was significantly associated with increased diabetes risk among individuals 13-20 years of age (HR 2.03; $p = 0.049$), whereas increasing HOMA-IR was associated with a moderately increased risk of diabetes in adult Aab+ individuals who were >20 years of age (HR 1.17; $p = 0.004$).

The accelerator hypothesis has been advanced for a number of reasons. Recent data demonstrate a steady increase in the incidence of type 1 diabetes of approximately 3-5% per year. Interestingly, recent studies have also revealed decreased representation of high-risk *HLA* alleles among participants with new-onset type 1 diabetes, with increasing penetrance in medium, low and very low risk genotypes [6, 37], suggesting an influence of environmental factors, such as weight status or insulin resistance. Indeed, rates of obesity have increased among all age groups over the past 20-30 years [20]. However, the prevalence of obesity has begun to plateau in some populations [38]. By contrast, the incidence of type 1 diabetes continues to increase, especially among the very young [39].

Analysis of the effect of metabolic factors in other cohorts has also been inconsistent. The DPT-1 study served as the precursor to the current TrialNet study. Results from DPT-1 showed that both HOMA1-IR and the ratio of the first phase insulin response to HOMA1-IR were significantly associated with progression to diabetes among Aab+ individuals. In contrast to DPT-1, our findings suggest that HOMA1-IR was not broadly associated with diabetes risk, but rather that increasing HOMA1-IR was associated with a moderately increased risk among older, adult individuals. Compared with DPT-1, which only screened participants in the US, TrialNet is an international study and includes more female participants and older relatives [31]. Interestingly, at least for participants ≥ 13 years of age, BMI was significantly higher in PTP participants than those enrolled in DPT-1 [31].

The German BABYDIAB study enrolled children born to parents with diabetes and also failed to reveal any relationship between BMI and HOMA1-IR and the development of islet autoimmunity [40]. In the US Diabetes Autoimmunity Study in the Young (DAISY), increased height growth velocity from age 2 years was associated with the development of islet autoimmunity; however, there was no association with BMI or weight [41]. Likewise, a recent analysis of the Pittsburgh cohort found no relationship between obesity and insulin resistance and the number of Aabs, progression to diabetes, or acceleration of diabetes at a younger age [42]. Data from the US SEARCH study [18], the Philadelphia Pediatric Diabetes Registry [43], and national Catalan [44] and Australian cohorts [45] have also failed to support the accelerator hypothesis. The Australian BABYDIAB study did uncover an association between BMI at age 2 years and islet autoimmunity, but progression to diabetes in this cohort was not assessed [46]. Thus, the preponderance of data from multiple cohorts, including ours, does not provide strong support for the accelerator hypothesis.

A number of important limitations illustrate the inherent difficulty of studying this question. First, participants are recruited into TrialNet and other cohorts based on having a blood relative with type 1 diabetes, such that genetic factors may play a predominant role. Indeed, high-risk *HLA* alleles were present in about two-thirds of our study population. Genome-wide association studies have identified additional risk loci including non-*HLA* genes such as *INS*, *PTPN22*, *GLIS3*, *IL2RA*, *UBASH3A* and *HLA* Class I alleles that confer a lower risk of progression to diabetes [47, 48]. Thus,

recruitment of future natural history studies may benefit from active incorporation of individuals with more diverse and lower risk *HLA* and non-*HLA* alleles, such that an influence of environmental factors may be more pronounced.

HOMA1-IR was used in our studies and many others and serves as a surrogate marker of insulin resistance. Practically incorporating a gold standard measure, such as the hyperinsulinaemic-euglycaemic clamp, into large epidemiological studies would be more precise but challenging and expensive. Moreover, the average BMI of the PTP cohort was 22 kg/m², and obese participants tended to be older. Thus, it would be useful to test our findings in a cohort enriched for younger participants with higher BMI values. In addition, BMI and HOMA1-IR were collected at baseline, but perhaps assessment of dynamic changes in metabolic variables would provide additional insight into how these factors influence risk [49]. To this end, we explored changes in HOMA1-IR and the development of diabetes, and interestingly found that individuals who progressed to diabetes exhibited a significantly larger increase in HOMA1-IR values compared with those who remained diabetes free.

Finally, our results revealed a significantly increased risk of diabetes among obese, peripubertal individuals aged 13-20 yrs. The incidence of type 1 diabetes exhibits a peak around the pubertal transition, a time associated with changes in secretion patterns of sex hormones that also impact insulin sensitivity. Thus, it is biologically plausible that obesity may compound these effects, and further increase diabetes risk in the peripubertal/early post-pubertal age group [41]. Whereas Tanner

staging was not collected for our study participants, data of this type would help better contextualise these findings [50].

In summary, we failed to demonstrate a pervasive effect of metabolic factors on diabetes risk. However, our results support a common sense approach towards maintenance of normal weight status in at-risk Aab+ individuals, especially during the pubertal transition and in older participants to avoid the development of insulin resistance. These data also suggest that efforts to identify other potentially modifiable environmental or lifestyle risk factors for type 1 diabetes should continue.

Acknowledgements

Parts of this study were presented in abstract form at the ICE/ENDO 2014 Conference, Chicago, IL, USA, 21–24 June 2014 by FAM and CEM.

Funding

The sponsor of the trial was the Type 1 Diabetes TrialNet Pathway to Prevention Study Group. Type 1 Diabetes TrialNet Pathway to Prevention Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01-DK103153, U01-DK085476, U01-DK103266 and the Juvenile Diabetes Research Foundation International (JDRF). This work was also partially supported by NIH grants R01 DK093954 and UC4 DK 104166 (to CEM), VA Merit Award I01BX001733 (to CEM) and JDRF grant SRA-2014-41 (to CEM, LAD and JSB). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, the US Department of Veterans Affairs or the United States Government, the JDRF or American Diabetes Association.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

FAM, CEM, PX and SG conceptualised the analysis, analysed and interpreted data, and wrote the manuscript. LAD, CJG, JSB, JMS and AP conceptualised the analysis, interpreted data and reviewed/edited the manuscript. CEM is the guarantor of this work, and all authors provided final approval of the manuscript prior to publishing.

Table 1 PTP participant characteristics by autoantibody status

Characteristics	Group 1:single Aab+ (n=1,310)	Group 2:multiple Aab+ (n=1,897)	Group 1 vs group 2 (p value)
Age at initial screening			
Median (Q1–Q3)	23.28 (10.51–38.14)	11.88 (7.52–19.44)	<0.001
Mean (SD)	23.66 (14.45)	14.8 (11.55)	<0.001
Sex, n (%)			<0.0001 ^b
Male	508 (38.78)	947 (49.92)	
Female	797 (60.84)	939 (49.50)	
Unknown/not reported	5 (0.38)	11 (0.58)	
Race, n (%)			0.01 ^b
White	1082 (82.60)	1645 (86.72)	
African-American	30 (2.29)	59 (3.11)	
Asian	20 (1.53)	21 (1.11)	
American Indian	4 (0.31)	4 (0.21)	
Native Hawaiian, Pacific Islander	3 (0.23)	2 (0.11)	
Other	134 (10.23)	133 (7.01)	
Unknown/not reported	37 (2.83)	33 (1.74)	
Ethnicity, n (%)			<0.001 ^b
Hispanic	203 (15.50)	187 (9.86)	
Non-Hispanic	1049 (80.08)	1622 (85.50)	
Unknown/not reported	58 (4.43)	88 (4.64)	
Relationship to proband, n (%)			<0.001 ^b
Sibling	472 (36.03)	1103 (58.14)	
Offspring	213 (16.26)	378 (19.93)	
Parent	482 (36.79)	245 (12.92)	
Other	128 (9.77)	142 (7.49)	
Unknown/not reported	15 (1.15)	29 (1.53)	
Number of positive Aabs at initial screen, n (%)			
0	0 (0.00)	0 (0.00)	
1	1310 (100.00)	0 (0.00)	
2	0 (0.00)	774 (40.80)	
3	0 (0.00)	556 (29.31)	
4	0 (0.00)	392 (20.66)	
5	0 (0.00)	175(9.23)	
HLA, n (%)			<0.001 ^b
DR3 and DR4 absent	243 (18.55)	215 (11.33)	
DR3 or DR4 present	876 (66.87)	1364(71.90)	
Unknown/not reported	191 (14.58)	318 (16.76)	
Weight category, n (%)			<0.001 ^b
Underweight	69 (5.27)	131 (6.91)	
Normal	611 (46.64)	1020 (53.77)	
Overweight ^a	278 (21.22)	282 (14.87)	
Obese ^a	250 (19.08)	263 (13.86)	
Unknown	102 (7.79)	201 (10.60)	
Weight (kg) mean (SD)	61.05 (27.26)	47.65 (26.67)	<0.001
Height (cm) mean (SD)	155.9 (22.55)	145.14 (26.02)	<0.001
BMI (percentile) mean (SD)	67.75 (28.33)	63.05 (29.0)	<0.001
HOMA1-IR mean (SD)	1.99 (2.08)	1.75 (1.46)	<0.001

^aObese defined as a BMI ≥ 30 kg/m² and/or BMI% $\geq 95\%$; overweight defined as BMI ≥ 25 kg/m² and < 30 kg/m² and/or BMI% $\geq 85\%$ and $< 95\%$; normal weight defined as BMI ≥ 18.5 kg/m² and < 25 kg/m² and/or BMI% $\geq 5\%$ and $< 85\%$; underweight defined as BMI ≤ 18.5 kg/m² and/or BMI% $\leq 5\%$. Reference group defined as normal weight

^b χ^2 *p* values, not including unknown/reported participants

Table 2 PTP participant characteristics by BMI category

Characteristic	Obese participants ^a (n=513)	Non-obese participants ^a (n=2,391)	Obese vs non-obese (p value)
Age at initial screening			<0.001
Median (Q1–Q3)	28.24 (11.07–38.87)	11.91 (7.29–23.99)	
Mean (SD)	25.37 (14.34)	16.75 (12.81)	
Sex, n (%)			0.44
Male	227 (44.25)	1103 (46.13)	
Female	285 (55.56)	1277 (53.41)	
Unknown/not reported	1 (0.19)	11 (0.46)	
Race, n (%)			0.009
White	407 (79.34)	2053 (85.86)	
African-American	22 (4.29)	60 (2.51)	
Other	63 (12.28)	234 (9.79)	
Unknown/not reported	21 (4.09)	44 (1.84)	
Number of positive Aabs at initial screen, n (%)			0.0004
1	250 (48.73)	958 (40.07)	
2+	263 (51.27)	1433 (59.93)	

^aObese defined as a BMI ≥ 30 kg/m² and/or BMI% $\geq 95\%$; non-obese includes underweight/normal/overweight participants

Table 3 Univariate results of possible risk factors with progression outcomes

Factor	Time to progression to multiple Aab+		Time to progression to type 1 diabetes	
	HR (95% CI)	<i>p</i> value	HR (95% CI)	<i>p</i> value
Age at initial screening	0.98 (0.97, 0.99)	0.001	0.95 (0.947, 0.96)	<0.001
Sex				
Female (ref)				
Male	1.36 (1.08, 1.71)	0.01	1.34 (1.15, 1.57)	<0.001
<i>HLA</i> (if <i>DR3</i> or <i>DR4</i>)				
Absent (ref)				
Present	1.38 (0.99, 1.93)	0.06	1.96 (1.45, 2.65)	<0.001
Relationship to proband				
Non-first degree (ref)				
First degree	1.52 (0.98, 2.37)	0.06	1.02(0.77, 1.35)	0.90
Race				
White (ref)				
African-American	0.68 (0.28, 1.66)	0.40	1.10(0.68, 1.78)	0.71
Other	0.63 (0.42, 0.92)	0.02	0.74(0.57, 0.98)	0.03
Aab positivity				
Single positive (ref)				
Multiple positive			8.31(6.46, 10.69)	<0.001
BMI categories				
Normal (ref)				
Underweight	0.89 (0.52, 1.09)	0.66	1.90(1.46, 2.47)	<0.001
Overweight ^a	0.64 (0.46, 0.88)	0.01	0.80(0.64, 1.00)	0.054
Obese ^a	0.80 (0.59, 1.09)	0.16	0.77(0.60, 0.98)	0.032
BMI (kg/m ²)	0.97 (0.95, 0.99)	0.01	0.93(0.92, 0.95)	<0.001
BMI%	0.994 (0.99, 0.99)	0.01	1.00(0.99, 1.01)	0.14

HOMA1-IR	1.02 (0.95, 1.09)	0.67	0.95(0.90, 1.02)	0.14
----------	-------------------	------	------------------	------

^aObese defined as a BMI ≥ 30 kg/m² and/or BMI% $\geq 95\%$; overweight defined as BMI ≥ 25 kg/m² and < 30 kg/m² and/or BMI% $\geq 85\%$ and $< 95\%$; normal weight defined as BMI ≥ 18.5 kg/m² and < 25 kg/m² and/or BMI% $\geq 5\%$ and $< 85\%$; underweight defined as BMI ≤ 18.5 kg/m² and/or BMI% $\leq 5\%$. Reference group defined as normal weight

Table 4 Multivariate analysis of progression of islet autoimmunity and progression to type 1 diabetes

Variable	Time to progression to multiple Aabs ^b		Time to progression to type 1 diabetes ^b	
	HR (95% CI) ^c	p value	HR (95% CI) ^c	p value
BMI (kg/m ²)	1.00 (0.97, 1.02)	0.73	1.01 (0.99, 1.03)	0.29
BMI%	1.00 (0.99, 1.01)	0.27	1.004 (1.0002, 1.007)	0.04
HOMA1-IR	0.96 (0.87, 1.07)	0.47	1.02 (0.95, 1.09)	0.56
BMI categories ^a				
Underweight vs normal	0.89 (0.50, 1.60)	0.70	0.99 (0.73, 1.35)	0.96
Overweight vs normal	0.84 (0.58, 1.21)	0.34	1.25 (0.98, 1.60)	0.08
Obese vs normal	1.01 (0.70, 1.45)	0.96	1.26 (0.96, 1.65)	0.10
Obese vs non-obese (overweight/normal/underweight)	1.20 (0.84, 1.69)	0.34	1.20 (0.92, 1.56)	0.18

^aObese defined as a BMI ≥ 30 kg/m² and/or BMI% $\geq 95\%$; overweight defined as BMI ≥ 25 kg/m² and < 30 kg/m² and/or BMI% $\geq 85\%$ and $< 95\%$; normal weight defined as BMI ≥ 18.5 kg/m² and < 25 kg/m² and/or BMI% $\geq 5\%$ and $< 85\%$; underweight defined as BMI ≤ 18.5 kg/m² and/or BMI% $\leq 5\%$. Reference group defined as normal weight

^bCox proportional hazard model adjusted by age at initial screen, sex, HLA risk, relationship to proband and race

^cHR defined per every one unit increase in measure for each continuous (BMI, BMI% and HOMA1-IR) variable

Table 5 Cox proportional hazard model of type 1 diabetes development with stratification by number of positive Aabs and age at initial screening

Variable	HR (95% CI)	<i>p</i> value ^b
Aab status ^b		
Confirmed single Aab+ (n=1,310)		
BMI (kg/m ²)	1.01 (0.96, 1.07)	0.74
BMI%	1.01 (0.99, 1.02)	0.24
Obese vs normal ^a	1.17 (0.54, 2.55)	0.68
Overweight vs normal ^a	1.20 (0.57, 2.50)	0.63
Underweight vs normal ^a	1.32 (0.40, 4.47)	0.65
Obese vs non-obese ^a	1.09 (0.53, 2.23)	0.82
HOMA1-IR	1.09 (0.93, 1.28)	0.30
Multiple Aab+ (n=1,897)		
BMI (kg/m ²)	1.01 (0.99, 1.04)	0.31
BMI%	1.00 (0.99, 1.01)	0.06
Obese vs normal ^a	1.31 (0.97, 1.75)	0.08
Overweight vs normal ^a	1.26 (0.96, 1.64)	0.09
Underweight vs normal ^a	1.07 (0.78, 1.47)	0.69
Obese vs non-obese ^a	1.24 (0.93, 1.64)	0.15
HOMA1-IR	1.05 (0.98, 1.13)	0.15
Age at initial screen ^b		
Age <13 years (n=1632)		
BMI%	1.01 (0.99, 1.01)	0.06
Obese vs normal ^a	1.28 (0.91, 1.80)	0.16
Overweight vs normal ^a	1.28 (0.95, 1.74)	0.11
Underweight vs normal ^a	1.00 (0.72, 1.38)	0.998
Obese vs non-obese ^a	1.23 (0.88, 1.71)	0.23
HOMA1-IR	0.99 (0.90, 1.09)	0.83
Age 13-20 years (n=532)		
BMI%	1.00 (0.99, 1.01)	0.65
Obese vs normal ^a	2.06 (1.02, 4.19)	0.045
Overweight vs normal ^a	1.37 (0.70, 2.67)	0.36
Underweight vs normal ^a	1.43 (0.33, 6.09)	0.63
Obese vs non-obese ^a	1.92 (0.96, 3.84)	0.064
HOMA1-IR	1.11 (0.96, 1.28)	0.15
Age ≥ 20 years (n=1,039)		
BMI (kg/m ²)	0.99 (0.95, 1.03)	0.57
BMI%	1.00 (0.99, 1.01)	0.80
Obese vs normal ^a	0.83 (0.45, 1.51)	0.53
Overweight vs normal ^a	0.97 (0.54, 1.77)	0.93
Underweight vs normal ^a	NA	NA
Obese vs non-obese ^a	0.83 (0.48, 1.45)	0.52
HOMA1-IR	1.17 (1.05, 1.31)	0.004

^aObese defined as a BMI ≥30 kg/m² and/or BMI% ≥95%; overweight defined as BMI ≥25 kg/m² and <30 kg/m² and/or BMI% ≥85% and <95%; normal weight defined as BMI ≥18.5 kg/m² and <25 kg/m² and/or BMI% ≥5% and <85%;

underweight defined as BMI ≤ 18.5 kg/m² and/or BMI% $\leq 5\%$. Reference group defined as normal weight, and non-obese defined as underweight/normal/overweight

^bCox proportional hazard model adjusted by age at initial screen, sex, *HLA* risk, relationship to proband, race and number of Aabs at initial screen

REFERENCES

- [1] Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends. *Diabetologia* 42: 1395-1403
 - [2] DIAMOND Project Group (2006) Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. *Diabetic medicine* 23: 857-866
 - [3] Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. *Lancet* 373: 2027-2033
 - [4] Lawrence JM, Imperatore G, Dabelea D, et al. (2014) Trends in incidence of type 1 diabetes among non-hispanic white youth in the United States, 2002-2009. *Diabetes* 63: 3938-3945
 - [5] Donath MY, Hess C, Palmer E (2014) What is the role of autoimmunity in type 1 diabetes? A clinical perspective. *Diabetologia* 57: 653-655
 - [6] Fourlanos S, Varney MD, Tait BD, et al. (2008) The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. *Diabetes care* 31: 1546-1549
 - [7] Redondo MJ, Yu L, Hawa M, et al. (2001) Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. *Diabetologia* 44: 354-362
 - [8] Bodansky HJ, Staines A, Stephenson C, Haigh D, Cartwright R (1992) Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population. *BMJ (Clinical research ed)* 304: 1020-1022
 - [9] Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. *The New England journal of medicine* 347: 911-920
 - [10] Schneider DA, von Herrath MG (2014) Potential viral pathogenic mechanism in human type 1 diabetes. *Diabetologia* 57: 2009-2018
 - [11] Vaarala O, Atkinson MA, Neu J (2008) The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. *Diabetes* 57: 2555-2562
 - [12] Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet* 358: 1500-1503
 - [13] Kimpimaki T, Kupila A, Hamalainen AM, et al. (2001) The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. *The Journal of clinical endocrinology and metabolism* 86: 4782-4788
 - [14] Howard SG, Lee DH (2012) What is the role of human contamination by environmental chemicals in the development of type 1 diabetes? *Journal of epidemiology and community health* 66: 479-481
 - [15] Wilkin TJ (2008) Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis. *Pediatric diabetes* 9: 23-32
-

- [16] Johansson C, Samuelsson U, Ludvigsson J (1994) A high weight gain early in life is associated with an increased risk of type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 37: 91-94
- [17] Knerr I, Wolf J, Reinehr T, et al. (2005) The 'accelerator hypothesis': relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. *Diabetologia* 48: 2501-2504
- [18] Dabelea D, D'Agostino RB, Jr., Mayer-Davis EJ, et al. (2006) Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. *Diabetes care* 29: 290-294
- [19] Kibirige M, Metcalf B, Renuka R, Wilkin TJ (2003) Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. *Diabetes care* 26: 2865-2870
- [20] Fryar CD CM, Ogden CL (2012) Prevalence of Obesity Among Children and Adolescents: United States, Trends 1963–1965 Through 2009–2010. Available from http://www.cdc.gov/nchs/data/hestat/obesity_child_09_10/obesity_child_09_10.pdf. accessed 29 March 2014.
- [21] Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP (2007) Role of insulin resistance in predicting progression to type 1 diabetes. *Diabetes care* 30: 2314-2320
- [22] Chase HP, Cuthbertson DD, Dolan LM, et al. (2001) First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. *The Journal of pediatrics* 138: 244-249
- [23] Sosenko JM, Skyler JS, Mahon J, et al. (2011) Validation of the Diabetes Prevention Trial-type 1 risk score in the TrialNet Natural History Study. *Diabetes care* 34: 1785-1787
- [24] Sosenko JM, Skyler JS, Mahon J, et al. (2014) Use of the Diabetes Prevention Trial-type 1 risk score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. *Diabetes care* 37: 979-984
- [25] Sosenko JM, Skyler JS, Mahon J, et al. (2012) The application of the Diabetes Prevention Trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. *Diabetes care* 35: 1552-1555
- [26] Skyler JS, Greenbaum CJ, Lachin JM, et al. (2008) Type 1 Diabetes TrialNet--an international collaborative clinical trials network. *Annals of the New York Academy of Sciences* 1150: 14-24
- [27] Mahon JL, Sosenko JM, Rafkin-Mervis L, et al. (2009) The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. *Pediatric diabetes* 10: 97-104
- [28] Yu L, Boulware DC, Beam CA, et al. (2012) Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. *Diabetes care* 35: 1213-1218
- [29] Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al. (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. *Diabetes care* 31: 1966-1971
- [30] Vehik K, Beam CA, Mahon JL, et al. (2011) Development of autoantibodies in the TrialNet Natural History Study. *Diabetes care* 34: 1897-1901
- [31] Sosenko JM, Mahon J, Rafkin L, et al. (2011) A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. *Pediatric diabetes* 12: 85-90
- [32] (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. *The New England journal of medicine* 346: 1685-1691
-


- [33] Ogden CL, Kuczmarski RJ, Flegal KM, et al. (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. *Pediatrics* 109: 45-60
- [34] American Diabetes Association (2014) Standards of medical care in diabetes--2014. *Diabetes care* 37(Suppl 1): S14-S80
- [35] Lin DY, L. J. Wei, and Z. Ying. (1993) Checking the Cox model with cumulative sums of Martingale-based residuals. *Biometrika* 80: 557-572
- [36] Erlich H, Valdes AM, Noble J, et al. (2008) HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes* 57: 1084-1092
- [37] Steck AK, Armstrong TK, Babu SR, Eisenbarth GS (2011) Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. *Diabetes* 60: 1045-1049
- [38] Ogden CL, Carroll MD, Kit BK, Flegal KM (2014) Prevalence of childhood and adult obesity in the United States, 2011-2012. *JAMA* 311: 806-814
- [39] (2000) Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. *Lancet* 355: 873-876
- [40] Winkler C, Marienfeld S, Zwillig M, Bonifacio E, Ziegler AG (2009) Is islet autoimmunity related to insulin sensitivity or body weight in children of parents with type 1 diabetes? *Diabetologia* 52: 2072-2078
- [41] Lamb MM, Yin X, Zerbe GO, et al. (2009) Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. *Diabetologia* 52: 2064-2071
- [42] Cedillo M, Libman IM, Arena VC, et al. (2015) Obesity, islet cell autoimmunity, and cardiovascular risk factors in youth at onset of type 1 autoimmune diabetes. *The Journal of clinical endocrinology and metabolism* 100: E82-86
- [43] Lipman TH, Levitt Katz LE, Ratcliffe SJ, et al. (2013) Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia Pediatric Diabetes Registry. *Diabetes care* 36: 1597-1603
- [44] Gimenez M, Aguilera E, Castell C, de Lara N, Nicolau J, Conget I (2007) Relationship between BMI and age at diagnosis of type 1 diabetes in a Mediterranean area in the period of 1990-2004. *Diabetes care* 30: 1593-1595
- [45] O'Connell MA, Donath S, Cameron FJ (2007) Major increase in type 1 diabetes: no support for the accelerator hypothesis. *Diabetic medicine* 24: 920-923
- [46] Couper JJ, Beresford S, Hirte C, et al. (2009) Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. *Diabetes care* 32: 94-99
- [47] Barrett JC, Clayton DG, Concannon P, et al. (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nature genetics* 41: 703-707
- [48] Steck AK, Dong F, Wong R, et al. (2014) Improving prediction of type 1 diabetes by testing non-HLA genetic variants in addition to HLA markers. *Pediatric diabetes* 15: 355-362
- [49] Barker JM, Goehrig SH, Barriga K, et al. (2004) Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. *Diabetes care* 27: 1399-1404
- [50] Ziegler AG, Meier-Stiegen F, Winkler C, Bonifacio E (2012) Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty--TEENDIAB: study design. *Pediatric diabetes* 13: 419-424
-

Supplemental Table 1: Univariate Results of Possible Risk Factors with Progression Outcomes

Factor	Time to progression to multiple Aab +		Time to progression to type 1 diabetes	
	HR (95% CI)	<i>p</i> -value	HR (95% CI)	<i>p</i> -value
Age at initial screening	0.98(0.97-0.99)	0.001	0.95(0.947-0.96)	<0.001
Gender Female (ref) Male	1.36(1.08-1.71)	0.01	1.34(1.15-1.57)	<0.001
HLA (If DR3 or DR4) Absent (ref) Present	1.38(0.99-1.93)	0.06	1.96(1.45-2.65)	<0.001
Relationship to proband Non-first Degree (ref) First Degree	1.52(0.98-2.37)	0.06	1.02(0.77-1.35)	0.90
Race White (ref) African American Other	0.68(0.28-1.66) 0.63(0.42-0.92)	0.40 0.02	1.10(0.68-1.78) 0.74(0.57-0.98)	0.71 0.03
Aab positivity Single positive (ref) Multiple positive			8.31(6.46-10.69)	<0.001
BMI categories [#] Normal/Underweight(ref) Overweight [#] Obese [#]	0.64(0.47-0.88) 0.81(0.59-1.10)	0.01 0.17	0.73(0.59-0.92) 0.71(0.56-0.89)	0.007 0.004
BMI (kg/m ²)	0.97(0.95-0.99)	0.01	0.93(0.92-0.95)	<0.001
BMI%	0.994(0.99-0.998)	0.01	1.00(0.99-1.01)	0.14
HOMA1-IR	1.02(0.95-1.09)	0.67	0.95(0.90-1.02)	0.14


[#] Obese defined as a BMI ≥ 30 and/or BMI% ≥ 95%, Overweight defined as BMI ≥ 25 and < 30 and/or BMI% ≥ 85% and < 95%. Reference group defined as normal or underweight.

Supplemental Figure 1:



Supplemental Figure 1: Final Analyses Cohort. Non-diabetic first, second, or third-degree relatives of individuals with type 1 diabetes were screened for the presence of pancreatic islet Aabs in a step-wise fashion. Confirmed Aab positive (Aab+) individuals were invited to participate in longitudinal observation with either semi-annual or annual monitoring. A total of 134,937 eligible individuals were screened from 2001 through June 30, 2014. A total of 2,299 individuals were confirmed on repeat testing to be single Aab (GAD65, insulin, or IA-2/ICA512) positive, while a total of 2,960 individuals were identified to be multiple Aab+ (GAD65, insulin, IA-2/ICA512, ICA, or ZnT8). Analyses presented here focus on those who had at least one monitoring visit (1,310 single Aab+ and 1,897 multiple Aab+ subjects). Within the single Aab+ group, 288 subjects progressed to multiple Aab+ status, while 68 individuals progressed to diabetes. Within the multiple Aab+ group, 579 individuals progressed to T1D. PTP = Pathway to Prevention; T1D = Type 1 Diabetes; Aab+ = autoantibody-positive; Aab- = autoantibody-negative. **Indicates confirmed positivity of the same type of islet autoantigen.*

Supplemental Figure 2:



normal/underweight	-○-	334	177	101	44	13
overweight	-●-	66	27	10	1	1
obese	-●-	79	44	19	4	1

Supplemental Figure 2: Time to Type 1 Diabetes by BMI Group in Subjects 13-20 years of age. Kaplan-Meier plots of diabetes-free survival in 532 PTP Participants 13-20 years of age stratified by BMI category. BMI category divisions included underweight (BMI <18.5 and/or BMI% <5%) combined with normal weight subjects (BMI \geq 18.5 kg/m² and < 25 kg/m² and/or BMI percentile \geq 5% and < 85%); overweight (BMI \geq 25 kg/m² and < 30 kg/m² and/or BMI percentile \geq 85% and < 95%); and obese (BMI \geq 30 kg/m² and/or BMI percentile \geq 95%). The HR of obese subjects is 2.03 (95% CI 1.00-4.10); p=0.049 vs. normal/underweight, adjusted for age at initial screen, gender, HLA risk, relationship to proband, race, and number of Aabs at initial screen. The HR of overweight vs. normal/underweight is 1.35 (95% CI 0.69-2.64); p=0.38, whereas the HR of obese vs. non-obese is 1.92 (95% CI 0.96-3.84); p=0.064.

Type 1 Diabetes TrialNet Study Group

Steering Committee: J.S. Skyler (University of Miami, Chair), M. Anderson (University of California, San Francisco), P. Antinozzi (Wake Forest University), M. Atkinson (University of Florida), M. Battaglia (San Raffaele University), D. Becker (University of Pittsburgh), P. Bingley (University of Bristol), E. Bosi (San Raffaele University), J. Buckner (Benaroya Research Institute), P. Colman (Walter & Eliza Hall Institute of Medical Research), L. DiMeglio (Indiana University), S. Gitelman, (University of California, San Francisco), R. Goland (Columbia University), P. Gottlieb (Barbara Davis Center for Childhood Diabetes), C. Greenbaum (Benaroya Research Institute), K. Herold (Yale University), R. Insel (Juvenile Diabetes Research Foundation), T. Kay (St Vincent's Institute of Medical Research), M. Knip (University of Helsinki), J. Krischer (University of South Florida), A. Lernmark (Skane University), J.B. Marks (University of Miami), A. Moran (University of Minnesota), J. Palmer (University of Washington), M. Peakman (King's College), L. Philipson (University of Chicago), A. Pugliese (University of Miami), P. Raskin (University of Texas Southwestern), M. Redondo (Baylor University), H. Rodriguez (University of South Florida), B. Roep (Leiden University Medical Center), W. Russell (Vanderbilt University), L. Spain (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]), D.A. Schatz (University of Florida), J. Sosenko (University of Miami), D. Wherrett (University of Toronto), D. Wilson (Stanford University), W. Winter (University of Florida), A. Ziegler (Forschergruppe Diabetes); Previous Members: C. Benoist (Joslin Diabetes Center), J. Blum (Indiana University), K. Bourcier, P. Chase (Barbara Davis Center for Childhood Diabetes), M. Clare-Salzler (University of Florida), R. Clynes (Columbia University), G. Eisenbarth (Barbara Davis Center for Childhood Diabetes), C. G. Fathman (Stanford University), G. Grave (National Institute of Child Health and Human Development), B. Hering (University of Minnesota), F. Kaufman (Children's Hospital Los Angeles), E. Leschek (NIDDK), J. Mahon (University of Western Ontario), K. Nanto-Salonen (University of Turku), G. Nepom (Benaroya Research Institute), T. Orban (Joslin Diabetes Center), R. Parkman (Children's Hospital Los Angeles), M. Pescovitz (Indiana University), J. Peyman (National Institute of Allergy and Infectious Disease), M. Roncarolo (San Raffaele University), P. Savage (NIDDK), O. Simell (University of Turku), R. Sherwin (Yale University), M. Siegelman (University of Texas Southwestern), A. Steck (Barbara Davis Center for Childhood Diabetes), J. Thomas (Vanderbilt University), M. Trucco (University of Pittsburgh), J. Wagner (University of Minnesota).

Executive Committee: Jay S. Skyler, Katarzyna Bourcier, Carla J. Greenbaum, Richard Insel, Jeffrey P. Krischer, Ellen Leschek, Lisa Rafkin, Lisa Spain. Past Members: Catherine Cowie, Mary Foulkes, Heidi Krause-Steinrauf, John M. Lachin, Saul Malozowski, John Peyman, John Ridge, Peter Savage, Stephanie J. Zafonte.

Chairman's Office: Jay S. Skyler, Carla J. Greenbaum, Norma S. Kenyon, Lisa Rafkin, Irene Santiago, Jay M. Sosenko.

TrialNet Coordinating Center (University of South Florida): Jeffrey P. Krischer, Brian Bundy, Michael Abbondandolo, Timothy Adams, Darlene Amado, Ilma Asif, Matthew Boonstra, David Boulware, Brian Bundy, Cristina Burroughs, David Cuthbertson, Mary Deemer, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Heather Guillette, Susan Geyer, Brian Hays, Courtney Henderson, Martha Henry, Kathleen Heyman, Belinda Hsiao, Christina Karges, Nichole Keaton, Amanda Kinderman, Pat Law, Ashely Leinbach, Cristin Linton, Shu Liu, Jennifer Lloyd, Jamie Malloy, Kristin Maddox, Julie Martin, Jessica Miller, Eric Milliot, Margaret Moore, Sarah Muller, Thuy Nguyen, Ryan O'Donnell, Vanessa Oduah, Jennifer Pilger, Amy Roberts, Kelly Sadler, Tina Stavros, Roy Tamura, Keith Wood, Ping Xu, Kenneth Young. Past Staff Members: Persida Alies, Franz Badias, Aaron Baker, Monica Bassi, Craig Beam, London Bounmananh, Susan Bream, Doug Freeman, Jessica Gough, Jinin Ginem, Moriah Granger, Mary Holloway Michelle Kieffer, Page Lane, Lavanya Nallamshetty, Yazandra Parrimon, Kate Paulus, Joy Ramiro, AQesha Luvon Ritzie, Archana Sharma, Audrey Shor, Xiaohong Song, Amanda Terry, Jeanne Weinberger, Margaret Wootten.

Previous Coordinating Center (George Washington University): John M. Lachin, Mary Foulkes, Pamela Harding, Heidi Krause-Steinrauf, Susan McDonough, Paula F. McGee, Kimberly Owens Hess, Donna Phoebus, Scott Quinlan, Erica Raiden.

NIDDK Staff: Judith Fradkin, Ellen Leschek, Lisa Spain. Past Member: Peter Savage.

Data Safety and Monitoring Board: Gerald Beck (Cleveland Clinic), Emily Blumberg (University of Pennsylvania), Chair, David Brillon (Cornell University), Rose Gubitosi-Klug (Case Western Reserve), Lori Laffel (Joslin Diabetes Center), Robert Veatch (Georgetown University), Dennis Wallace (Research Triangle Institute). Past Members: Jonathan Braun (University of California Los Angeles), Ake Lernmark (Lund University), Bernard Lo (University of California San Francisco), Herman Mitchell (Rho Inc.), Ali Naji (University of Pennsylvania), Jorn Nerup (University of Copenhagen), Trevor Orchard (University of Pittsburgh), Michael Steffes (University of Minnesota), Anastasios Tsiatis (North Carolina State University), Bernard Zinman (University of Toronto).

Infectious Disease Safety Committee: Brett Loechelt (Children's National Medical Center) (Medical Monitor), Lindsey Baden (Harvard University), Michael Green (University of Pittsburgh), Adriana Weinberg (University of Colorado).

Laboratory Directors: Santica Marcovina (University of Washington), Jerry P. Palmer, Adriana Weinberg, Liping Yu (University of Colorado Barbara Davis Center for Childhood Diabetes), Sunanda Babu (University of Colorado Barbara Davis Center for Childhood Diabetes) William Winter (University of Florida). Past Member: George S. Eisenbarth (late).

Protocol Chair Committee: Polly Bingley, Raphael Clynes, Linda DiMeglio, George Eisenbarth, Carla Greenbaum, Brian Hays, Jeffrey Krischer, Ellen Leschek, Jennifer Marks, Della Matheson, Lisa Rafkin, Henry Rodriguez, Jay Skyler, Jay Sosenko, Lisa Spain, Darrell Wilson.

Clinical Center Staff Involved in this Protocol:

Baylor College of Medicine: Maria Redondo, David Gomez, Andrene McDonald, Sandra Pena, Massimo Pietropaolo, Kathy Shippy.

Benaroya Research Institute, Seattle: Carla Greenbaum, Emily Batts, Tyler Brown, Jane Buckner, Angela Dove, Marissa Hammond, Deborah Hefty, Jani Klein, Kristen Kuhns, McKenzie Letlau, Sandra Lord, Marli McCulloch-Olson, Lisa Miller, Gerald Nepom, Jared Odegard, Mary Ramey, Elaine Sachter, Marissa St. Marie, Kimberly Stickney, Dana VanBuecken, Ben Vellek, Christine Webber. Past Members: Laurie Allen, Jenna Bollyk, Nicole Hilderman, Hebatullah Ismail, Steve Lamola, Srinath Sanda, Heather Vendettuoli, David Tridgell.

Children's Hospital Los Angeles: Roshanak Monzavi, Meredith Bock, Lynda Fisher, Mary Halvorson, Debra Jeandron, Mimi Kim, Jamie Wood. Past Members: Mitchell Geffner, Francine Kaufman, Robertson Parkman, Christine Salazar.

Columbia University, New York: Robin Goland, Raphael Clynes, Steve Cook, Matthew Freeby, Mary Pat Gallagher, Rachelle Gandica, Ellen Greenberg, Amy Kurland, Sarah Pollak, Amy Wolk. Past Members: Mary Chan, Linda Koplmae, Elizabeth Levine, Kelly Smith, Jeniece Trast.

Indiana University, Indianapolis: Linda DiMeglio, Janice Blum, Carmella Evans-Molina, Robin Hufferd, Bonnie Jagielo, Christy Kruse, Vanessa Patrick, Mark Rigby, Maria Spall, Kim Swinney, Jennifer Terrell. Past Members: Lyla Christner, LeeAnn Ford, Sheryl Lynch, Martha Menendez, Patricia Merrill, Mark Pescovitz (late), Henry Rodriguez.

Joslin Diabetes Center, Boston: Cielo Alleyn, David Baidal, Steve Fay, Jason Gaglia, Brittany Resnick, Sarah Szubowicz, Gordon Weir. Past Members: Ronald Benjamin, Debbie Conboy, Andrea deManbey, Richard Jackson, Heyam Jalahej, Tihmar Orban, Alyne Ricker, Joseph Wolfsdorf, Hui H. Zhang.

Stanford University: Darrell Wilson, Tandy Aye, Bonita Baker, Karen Barahona, Bruce Buckingham, Kerry Esrey, Trudy Esrey, Garry Fathman, Radhika Snyder. Past Members: Beenu Aneja, Maya Chatav, Oralía Espinoza, Eliana Frank, Jenny Liu, Jennifer Perry, Rebecca Pyle, Alison Rigby, Kristin Riley, Adriana Soto.

University of California San Francisco: Stephen Gitelman, Saleh Adi, Mark Anderson, Ashley Berhel, Kathy Breen, Kathleen Fraser, Andrea Gerard-Gonzalez, Paula Jossan, Robert Lustig, Sara Moassesfar, Amy Mugg, David Ng, Priya Prahalod, Martha Rangel-Lugo, Srinath Sanda, Joshua Tarkoff, Christine Torok, Rebecca Wesch. Past Members: Ivy Aslan, Jeanne Buchanan, Jennifer Cordier, Celia Hamilton, Louise Hawkins, Thu Ho, Anjali Jain, Karen Ko, Theresa Lee, Shelly Phelps, Stephen Rosenthal, Taninee Sahakitrungruang, Lorraine Stehl, Lisa Taylor, Marcia Wertz, Jenise Wong.

University of Chicago: Louis Philipson, Rosemary Briars, Nancy Devine, Elizabeth Littlejohn. Past Member: Tiffany Grant.

University of Colorado Barbara Davis Center for Childhood Diabetes, Denver: Peter Gottlieb, Georgeanna Klingensmith, Andrea Steck, Aimon Alkanani, Kimberly Bautista, Ruth Bedoy, Aaron Blau, Betsy Burke, Laraine Cory, MyLinh Dang, Lisa Fitzgerald-Miller, Alex Fouts, Vicky Gage, Satish Garg, Patricia Gesauldo, Raymond Gutin, Cory Hayes, Michelle Hoffman, Kaitlin Ketchum, Nyla Logsdan-Sackett, David Maahs, Laurel Messer, Lisa Meyers, Aaron Michels, Stesha Peacock, Marian Rewers, Perla Rodriguez, Flor Sepulbeda, Rachel Sippl, Andrea Steck, Iman Taki, Bao-Khan Tran, Tuan Tran, R. Paul Wadwa, Philip Zeitler. Past Members: Jennifer Barker, Sandra Barry, Laurie Birks, Leah Bomsburger, Terra Bookert, Leah Briggs, Patricia Burdick, Rosio Cabrera, Peter Chase, Erin Cobry, Amy Conley, Gabrielle Cook, Joseph Daniels, Dominic DiDomenico, Jennifer Eckert, Angelica Ehler, George Eisenbarth (late), Pamela Fain, Rosanna Fiallo-Scharer, Nicole Frank, Hannah Goettle, Michelle Haarhues, Sherrie Harris, Lauren Horton, John Hutton (late), Joy Jeffrey, Rachael Jenison, Kelly Jones, Whitney Kastelic, Maria Amelia King, Debbie Lehr, Jenna Lungaro, Kendra Mason, Heather Maurer, Luy Nguyen, Allison Proto, Jaime Realsen, Kristina Schmitt, Mara Schwartz, San Skovgaard, Jennifer Smith, Brandon Vanderwel, Mary Voelmle, Rebecca Wagner, Amy Wallace, Philip Walravens, Laurie Weiner, Becky Westerhoff, Emily Westfall, Katina Widmer, Hali Wright.

University of Florida, Gainesville: Desmond Schatz, Annie Abraham, Mark Atkinson, Miriam Cintron, Michael Clare- Salzler, Jessica Ferguson, Michael Haller, Jennifer Hosford, Diane Mancini, Hank Rohrs, Janet Silverstein, Jamie Thomas, William Winter. Past Members: Gloria Cole, Roberta Cook, Ryan Coy, Elena Hicks, Nancy Lewis.

University of Miami: Jennifer Marks, Alberto Pugliese, Carlos Blaschke, Della Matheson, Alberto Pugliese, Natalia Sanders-Branca, Jay Sosenko. Past Members: Luz Arazo Ray Arce, Mario Cisneros, Samir Sabbag.

University of Minnesota, Minneapolis: Antoinette Moran, Carrie Gibson, Brian Fife, Bernhard Hering, Christine Kwong, Janice Leschyshyn, Brandon Nathan, Beth Pappenfus, Anne Street. Past Members: Mary Ann Boes, Sarah Peterson Eck, Lois Finney, Theresa Albright Fischer, Andrea Martin, Chenai Jacqueline Muzamhindo, Missy Rhodes, Jennifer Smith, John Wagner, Bryan Wood.

University of Pittsburgh: Dorothy Becker, Kelli Delallo, Ana Diaz, Barbara Elnyczky, Ingrid Libman, Beata Pasek, Karen Riley, Massimo Trucco. Past Members: Brian Copemen, Diane Gwynn, Frederico Toledo.

University of South Florida: Henry Rodriguez, Sureka Bollepalli, Frank Diamond, Emily Eyth, Danielle Henson, Anne Lenz, Dorothy Shulman.

University of Texas Southwestern, Dallas: Phillip Raskin, Soumya Adhikari, Brian Dickson, Erin Dunnigan, Ildiko Lingvay, Lourdes Pruneda, Maria Ramos-Roman, Philip Raskin, Chanhaeng Rhee, John Richard, Mark Siegelman, Daytheon Sturges, Kathryn Sumpter, Perrin White. Past Members: Marilyn Alford, Jamie Arthur, M. Larissa Aviles-Santa, Erica Cordova, Renee Davis, Stefani Fernandez, Steve Fordan, Tauri Hardin, Aris Jacobs, Polina Kaloyanova, Ivanna Lukacova-Zib, Sasan Mirfakhraee, Alok Mohan, Hiroshi Noto, Oralenda Smith, Nenita Torres.

University of Toronto: Diane Wherrett, Diana Balmer, Lesley Eisel, Roze Kovalakovska, Mala Mehan, Farah Sultan. Past Members: Brenda Ahenkorah, Jose Cevallos, Natasha Razack, Mary Jo Ricci, Angela Rhode, Mithula Srikandarajah, Rachel Steger.

Vanderbilt University, Nashville: William E. Russell, Margo Black, Faith Brendle, Anne Brown, Daniel Moore, Eric Pittel, Alyssa Robertson, April Shannon, James W. Thomas.

Yale University, New Haven: Kevan Herold, Laurie Feldman, Robert Sherwin, William Tamborlane, Stuart Weinzimer.

International Clinical Center Staff involved in this Protocol:

Hospital District of Southwest Finland: Jorma Toppari, Tiina Kallio, Maarit Kärkkäinen, Elina Mäntymäki, Tiina Niininen, Birgitta Nurmi, Petro Rajala, Minna Romo, Sointu Suomenrinne.

Past Members: Kirsti Näntö- Salonen, Olli Simell, Tuula Simell.

San Raffaele Hospital (Italy): Emanuele Bosi, Manuela Battaglia, Eleonora Bianconi, Riccardo Bonfanti, Pauline Grogan, Andrea Laurenzi, Sabina Martinenghi, Franco Meschi, Matteo Pastore.

Past Members: Luca Falqui, Maria Teresa Muscato, Matteo Viscardi.

University of Bristol (United Kingdom): Polly Bingley, Harriet Castleden, Nicola Farthing, Sam Loud, Claire Matthews, Jennifer McGhee, Ann Morgan, Joanna Pollitt. Past Members: Rebecca Elliot-Jones, Carole Wheaton.

University of Helsinki: Mikael Knip, Heli Siljander, Heli Suomalainen.

Walter and Eliza Hall Institute of Medical Research (Australia): Peter Colman, Felicity Healy, Shelley Mesfin, Leanne Redl, John Wentworth, Jinny Willis. Past Members: Maree Farley, Leonard Harrison, Christine Perry, Fiona Williams.

5/1/15 TrialNet On-line List of Affiliate Investigators.

TrialNet Affiliates: Aberdeen, Scotland: A. Mayo, J. Paxton, V. Thompson; Ajo, AZ- L. Volin; Akron, OH- C. Fenton, L. Carr, E. Lemon, M Swank; Albany, NY- M.K. Luidens, M. Salgam, V. Sharma; Albuquerque, NM- D. Schade, C. King; Ames, IN- R. Carano, J. Heiden; Anchorage, AK- N.D Means, L. Holman; Ann Arbor, MI- I. Thomas, D. Madrigal, T. Muth, C.L. Martin, C. Plunkett, C. Ramm, R.J. Auchus; Asheville, NC- W. Lane, E. Avots, M. Buford, C. Hale, J. Hoyle, B. Lane; Atlanta, GA- A. Muir, S. Shuler, N. Raviele, E. Ivie, M. Jenkins, K. Lindsley, I. Hansen, D.O. Fadoju, E.I. Felner, B. Bode, R. Hosey, J. Sax; Auckland, NZ - C. Jefferies, S. Mannering, R. Prentis; Augusta, GA- J.X. She, M. Stachura, D. Hopkins, J. Williams, L. Steed, E. Asatapova; Austin, TX- S. Nunez, S. Knight, P. Dixon; Bakersfield, CA- J. Ching; Baltimore, MD- T. Donner, S. Longnecker, K. Abel, K. Arcara, S. Blackman, L. Clark, D. Cooke, L. Plotnick- P.A. Levin, L. Bromberger, K. Klein; Bangor, ME- K. Sadurska, C. Allen, D. Michaud, H. Snodgrass; Bartlett, TN- G. Burghen, S. Chatha, C. Clark; Baton Rouge, LA- J. Silverberg, C. Wittmer, J. Gardner, C. LeBoeuf ; Belfast, Ireland- P. Bell, O. McGlore, H. Tennes, N. Alba; Bend, OR- M. Carroll, L. Baert, H. Beaton, E. Cordell, A. Haynes, C. Reed, K. Lichter, P. McCarthy, S. McCarthy, T. Monchamp, J. Roach, S. Manies; Billings, MT- F. Gunville, L. Marosok, T. Nelson, K. Ackerman, J. Rudolph, M. Stewart; Birmingham, AL- K. McCormick, S. May, T. Falls; Birmingham, UK - T. Barrett, K. Dale, L. Makusha, C. McTernana, K. Penny-Thomas, K. Sullivan, P. Narendran, J. Robbie, D. Smith; Boise, ID- R. Christensen, B. Koehler, C. Royal, T. Arthur, H. Houser, J. Renaldi, S. Watsen; Bonita, CA- P. Wu, L. Lyons, B. House, J. Yu; Bournemouth, UK- H. Holt, M. Nation, C. Vickers, R. Watling; Bronx, NY- R. Heptulla, J. Trast, C. Agarwal, D.J. Newell, R. Katikaneni; Brunley, UK- C. Gardner, A. Del Rio, A. Logan, H. Collier, C. Rishton, G. Whalley, A. Ali, S. Ramtoola; Buffalo, NY- T. Quattrin, L. Mastrandea, A.J. House, M. Ecker; Calgary, AB- C. Huang, C. Gougeon, J. Ho, D. Pacuad; Cambridge, UK- D. Dunger, J. May, C. O'Brien, C. Acerini, B. Salgin, A. Thankamony, R. Williams; Chapel Hill, NC- J. Buse, G. Fuller, M. Duclos, J. Tricome, H. Brown, D. Pittard; Charleston, SC- D. Bowlby, A. Blue, T. Headley; Charleston, WV- S. Bendre, K. Lewis, K. Sutphin; Charlottesville, VA- C. Soloranzo, J. Puskaric, H. Madison; Chattanooga, TN- M. Rincon, M. Carlucci, R. Shridharani, B. Rusk, E. Tessman, D.M. Huffman, H. Abrams, B. Biederman, M.D. Jones, V. Leathers; Chicago, IL- W. Brickman, P. Petrie, D. Zimmerman, J. Howard, L. Miller, R. Alemzadeh, D.V. Mihailescu, R. Melgozza-Walker, N. Abdulla, C. Boucher-Berry, D. Ize-Ludlow, R. Levy, C. Swenson Brousell; Christchurch, NZ- R. Scott, H. Heenan, H. Lunt, D. Kendall, J. Willis, B. Darlow; Cincinnati, OH- N. Crimmins, D. Edler, T. Weis, C. Schultz; Cleveland, OH- D. Rogers, D. Latham, C. Mawhorter, C. Switzer, W. Spencer, P. Konstantinopoulos, S. Broder, J. Klein; Colombia, MO- B. Bachrach, M. Gardner, D. Eichelberger; Columbia, SC- L. Knight, L. Szadek, G. Welnick, B. Thompson; Columbus, OH- R. Hoffman, A. Revell, J. Cherko, K. Carter, E. Gilson, J. Haines, G. Arthur, B. Bowen, W.B. Zipf, P. Graves, R.A. Lozano, D. Seiple, K. Spicer; Concord, CA- A. Chang, J. Fregosi, J. Harbinson, C. Paulson, S. Stalters, P. Wright, D. Zlock; Cooperstown, NY- A.E. Freeth, J. Victory; Crystal Lake, IL- H. Maheshwari, A. Maheshwari, T. Holmstrom, J. Bueno; Danbury, CT- R. Arguello, J. Ahern, L. Noreika, V. Watson, S. Hourse; Dayton, OH- P. Breyer, C. Kissel, Y. Nicholson, M. Pfeifer, S. Almazan; Denver, CO- J. Bajaj, M. Quinn, K. Funk, J. McCance, E. Moreno, R. Veintimilla, A. Wells; Des Moines, IA- J. Cook, S. Trunnel; Detroit, MI- D. Transue, J. Surhigh, D. Bezzaire, K. Moltz, E. Zacharski; Downers Grove, IL- J. Henske, S. Desai, K. Frizelis, F. Khan; Duluth, MN- R. Sjoberg, K. Allen; Dunedin, NZ- P.P Manning, G. Hendry, B. Taylor, S. Jones; Edmonton, AB- R. Couch, R. Danchak, D. Lieberman; El Paso, TX- W. Strader, M.E. Bencomo; Escondido, CA- T. Bailey, L. Bedolla, C. Roldan; Exeter, UK- C. Moudiotis, B. Vaidya, C. Anning, S. Bunce, S. Estcourt, E. Folland, E. Gordon, C. Harrill, J. Ireland, J. Piper, L. Scaife, K. Sutton, S. Wilkins, M. Costelloe, J. Palmer; Fargo, ND- L. Casas, C. Miller, M. Burgard, C. Erickson, J. Hallanger-Johnson; Florence, SC- P. Clark, W. Taylor; Florissant, MO- J. Galgani; Fresno, CA- S. Banerjee, C. Banda, D. McEowen, R. Kinman; Garran, Australia- A. Lafferty, S. Gillett, C. Nolan, M. Pathak; Grand Folks, ND- L. Sondrol, T. Hjelle, S. Hafner, J. Kotrba, R. Hendrickson; Grand Rapids, MI- A.P. Cemeroglu, T. Symington, M. Daniel, Y. Appiagyei-Dankah, D.C. Postellon, M.S. Racine, L. Kleis; Greenville, NC- K. Barnes, S.E. Godwin, H. McCullough, K. Shaheen, G. Buck, L. Noel, M.L. Warren; Greenville, SC- S. Weber, S.M. Parker, I. Gillespie, B.A. Nelson, C. Frost, J. Amrhein, E.C. Moreland, A. Hayes, J. Peggram; Hackensack, NJ- J. Aisenberg, M.E. Riordan, J. Zasa; Halifax,

NS- E. Cummings, K. Scott, T. Pinto, A. Mokashi; Hamilton, ON- K. McAssey, E. Helden; Harrogate, UK- P. Hammond, L. Dinning, S. Rahman, S. Ray; Hartford CT- C. Dimicri, S. Guppy, H. Nielsen; Henderson, NV- C.K. Vogel, C. Ariza, L. Morales; Hershey, PA- Y.T. Chang, R.A. Gabbay, L. Ambrocio, L. Manley; Hollywood, FL- R. Nemery, W. Charlton, P. Smith, L. Kerr, B. Steindel-Kopp, M. Alamaguer; Honolulu, HI- E. Tabisola-Nuesca, A. Pendersen, N. Larson, H. Cooper-Olviver, D. Chan, D. Fitz-Patrick, T. Carreira, Y. Park, R. Ruhaak; Idaho Falls, ID- D. Liljenquist, G. Browning, T. Coughenour, M.B. Sulk; Iowa City, IA- E. Tsalikan, M. Tansey, J. Cabbage; Jackson, MS- N. Dixit, S. Pasha, M. King, K. Adcock, H. Atterberry; Jacksonville, FL- L. Fox, K. Englert, N. Mauras, J. Permuy, K. Sikes; Joliet, IL- T. Berhe, B. Guendling, L. McLennan, L. Paganessi, C. Murphy; Kalamazoo, MI- M.B. Draznin, M. Kamboj, S. Sheppard; Kalispell, MT- V. Lewis, L. Coates; Kansas City, MO- W. Moore, G. Babar, J. Bedard, D. Brenson-Hughes, J. Cernich, M. Clements, R. Duprau, S. Goodman, L. Hester, L. Huerta-Saenz, A. Karmazin, T. Letjen, S. Raman; Kingsport, TN- D. Morin, W. Bestermann, E.J. Morawski, J.L. White, A. Brockmyer, R. Bays, S. Campbell, A. Stapleton, N. Stone, A. Donoho, H. Everett, H. Hensley, M. Johnson, C. Marshall, N. Skirvin, P. Taylor, R. Williams, L. Ray, C. Wolverton; Knoxville, TN- D.A. Nickels, C. Dothard; Lake Success, NY- P.W. Speiser, M. Pellizzari, L. Bokor; Las Vegas, NV- K. Izuora, S. Abdelnour, P. Cummings, S. Paynor, M. Leahy, M. Riedl, S. Shockley, R. Saad, T. Briones; Lebanon, NH- S. Casella, C. Herz, K. Walsh; Leichestre, UK- J. Greening, F. Hay, S. Hunt, N. Sikotra, L. Simons; Lexington, KY- D.G. Karounos, R. Oremus, L. Dye, L. Myers, D. Ballard, W. Miers, R. Sparks; Little Rock, AR- K.M. Thraikill, K. Edwards, J. Fowlkes, S. Kemp, A. Morales, L. Holland, L. Johnson; Liverpool, UK- P. Paul, A. Ghatak, K. Phelen, H. Leyland, T. Henderson; Livingston, NJ- D. Brenner, E. Oppenheimer, I. Mamkin, C. Moniz; London, ON- C. Clarson, M. Lovell; Los Angeles, CA- A. Peters, V. Ruelas, D. Borut, D. Burt, M. Jordan, S. Castilla, P. Flores, M. Ruiz, L. Hanson, J. Green-Blair, R.J. Sheridan; Louisville, KY- K.A. Wintergerst, G. Pierce, A. Omoruyi, M. Foster, S. Kingery; Lubbock, TX- A. Lunsford, I. Cervantes, T. Parker, P. Price, J. Urben; Manchester, UK- I. Doughty, H. Haydock, V. Parker; Melbourne, Australia- P. Bergman, S. Duncum, C. Rodda; Memphis, TN- A.D. Thomas, R. Ferry, D. McCommon, J. Cockroft; Mesa, AZ- A. Perelman, R. Calendo; Miami, FL- C. Barrera, E. Arce-Nunez, Y. Martinez, M. De la Portilla, I. Cardenas, L. Garrido, M. Villar; Milan, Italy- R. Lorini, E. Calandra, G. D'Annuzio, K. Perri, N. Minuto, C. Rebora, R. Callegari; Milwaukee, WI- O. Ali, J. Kramer, B. Auble, S. Cabrera, P. Donohoue, R. Fiallo-Scharer, M. Hessner, P. Wolfgram, A. Kansra, N. Bettin, R. McCuller, A. Miller; Mineola, NY- S. Accacha, J. Corrigan, E. Fiore, R.L. Levine, T.A. Mahoney; Montreal, QC- C. Polychronakos, V. Gagne; Morristown, NJ- H. Starkman, M. Fox, D. Chin, F. Melchionne, L.A. Silverman; New Brunswick, NJ- I. Marshall, L. Cerracchio, J. Cruz, A. Viswanathan, J. Wilson; New Orleans, LA- S. Chalew, S. Valley, S. Layburn, A. Lala, P. Clesi, M. Genet, G. Uwaifo, A. Charron, T. Allerton, W. Cefalu, L. Melendez-Ramirez, R. Richards, C. Alleyn, E. Gustafson, M. Lizanna; New Port Richey, FL- J. Wahlen, S. Aleiwe, M. Hansen, H. Wahlen; New York, NY- C.J. Levy, A. Bonaccorso, R. Rapaport, Y. Tomer, D. Chia, M. Goldis, L. Iazzetti, M. Klein, C. Levister, L. Waldman, E. Wallach, M.O. Regelmann, Z. Antal, M. Aranda, C. Reynolds; Newcastle Upon Tyne, UK- N. Leech, D. Wake, C. Owens, M. Burns, J. Wotherspoon, A. Murray, K. Short, G. Curry, S. Kelsey, J. Lawson, J. Porter, S. Stevens, E. Thomson, S. Winship, L. Wynn; Newton, NZ- E. Wiltshire, J. Krebs, P. Cresswell, H. Faherty, C. Ross; Norfolk, VA- A. Vinik, P. Barlow, M. Bourcier, M.L. Nevoret; North Adelaide, Australia- J. Couper, S. Beresford; Norwich, UK- N. Thalagne, H. Roper, J. Gibbons, J. Hill, S. Balleaut, C. Brennan, J. Ellis-Gage, L. Fear, T. Gray, L. Jones, C. McNerney, L. Pointer, N. Price, K. Few, D. Tomlinson; Nottingham, UK- L. Denvir, J. Drew, T. Randell, P. Mansell, S.A Bell, S. Butler, Y. Hooton, H. Navarra, A. Roper, G. Babington, L. Crate, H. Cripps, A. Ledlie, C. Moulds, R. Norton, B. Petrova, O. Silkstone, C. Smith; Oak Lawn, IL- K. Ghai, M. Murray, V. Viswanathan, M. Henegan, O. Kawadry; Oakland, CA- J.A. Olson, L. Patterson, T. Ahmad, B. Flores; Oklahoma City, OK- D. Domek, S. Domek, K. Copeland, M. George, J. Less, T. Davis, M. Short; Olympia Fields, IL- A. Dwarakanathan, P. O'Donnell; Omaha, NE- B. Boerner, L. Larson, M. Phillips, M. Rendell, K. Larson, C. Smith, K. Zebrowski, L. Kuechenmeister, M. Thevarayapillai; Orange, CA- M. Daniels, H. Speer, N. Forghani, R. Quintana, C. Reh, A. Bhangoo; Orlando, FL- P. Desrosiers, L. Ireland, T. Mislá, C. Torres, S. Wells, J. Villar, M. Yu, D. Berry, D. Cook, J. Soder, A. Powell; Ormskirk, UK- M. Ng, M. Morrison, Z. Haslam; Ottawa, ON- M. Lawson, B. Bradley, J. Courtney, C. Richardson, C. Watson, E. Keely, D. DeCurtis; Palm Beach Gardens, FL- M.

Vaccarcello-Cruz, Z. Torres, K. Sandberg; Pensacola, FL- H. Hsiang, B. Joy, D. McCormick, A. Powell, H. Jones, J. Bell, S. Hargadon, S. Hudson, M. Kummer; Peoria, IL- S. Sauder, E. Sutton, K. Gensel, R. Aguirre-Castaneda, V. Benavides Lopez, D. Hemp, S. Allen, J. Stear; Perth, Australia- E. Davis, T. Jones, A. Roberts, J.A Dart, N. Paramalingam; Philadelphia, PA- L.E. Levitt Katz, N. Chaudhary; K.M. Murphy, S.M. Willi, B. Schwartzman; Phoenix, AZ- C. Kapadia, D. Larson, D. McClellan, G. Shaibai, L.A. Kelley, G. Villa, C. Kelley, R. Diamond, M. Kabbani, T. Dajani, F. Hoekstra, M. Magorno; Pittsburgh, PA- J. Holst, V. Chauhan, N. Wilson, P. Bononi, M. Sperl; Plymouth, UK- A. Millward, M. Eaton, L. Dean; Portland, ME- J. Olshan, H. Renna, C. Milliard; Portland, OR- D. Snyder, S. Beaman, K. Burch, J. Chester, A. Ahmann, B. Wollam, D. DeFrang, R. Fitch, K. Jahnke, K. Hanavan, B. Klopfenstein, L. Nicol, R.W. Bergstrom, T. Noland; Poughkeepsie, NY- J. Brodksy, L. Bacon; Providence, RI- J.B. Quintos, L.S. Topor, S. Bialo, B. Bancroft, A.G. Soto; Raleigh, NC- W. Lagarde, H. Lockemer, T. Vanderploeg; Rancho Cucamonga, CA- M.A Ibrahim, M. Huie, V. Sanchez; Rapid City, SD- R. Edelen, R. Marchiando, J. Palmer, T. Repas, M. Wasson, P. Auker, J. Culbertson, T. Kieffer, D. Voorhees, T. Borgwardt, L. DeRaad; Reno, NV- K. Eckert; Richland, WA- E. Isaacson, H. Kuhn, A. Carroll, M. Schubert; Richmond, VA- G. Francis, S. Hagan, T. Le, M. Penn, E. Wickham; Rio Piedras, PR- C. Leyva, K. Rivera, J. Padilla, I. Rodriguez; Rochester, NY- N. Jospe, J. Czyzyk, B. Johnson; Sacramento, CA- U. Nadgir, N. Marlen, G. Prakasam, C. Rieger, N. Glaser, E.C. Heiser, B. Harris; Salt Lake City, UT C. Foster, H. Slater, K. Wheeler, D.L Donaldson, M. Murray; San Antonio, TX- D.E. Hale, R. Tragus, D.R. Word, J. Lynch, L. Pankratz, W. Rogers; San Diego, CA- R. Newfield, S. Holland, M. Hashiguchi, M. Gottschalk, A. Philis-Tsimikas, R. Rosal, S. Franklin, S.M. Guardado; San Francisco, CA- N. Bohannon, M. Garcia; San Jose, CA- T. Aguinaldo, J. Phan, V. Barraza, D. Cohen; Santa Barbara, CA- J. Pinsker, U. Khan, J. Wiley, L. Jovanovic; Santa Clara, CA- P. Misra, M. Wright, D. Cohen, K. Huang; Scottsbluff, NE- M. Skiles, S. Maxcy; Seattle, WA- C. Pihoker, K. Cochrane, J. Fosse, S. Kearns, M. Klingsheim; Sheffield, UK- N. Wright, L. Viles, H. Smith, S. Heller, M. Cunningham, A. Daniels, L. Zeiden, J. Field, R. Walker; Sioux Falls, SD- K.J. Griffin, L. Bartholow, C. Erickson, J. Howard, B. Krabbenhoft, C. Sandman, A. Vanveldhuizen, J. Wurlger, A. Zimmerman, K. Hanisch, L. Davis-Keppen; South Brisbane, Australia- A. Cotterill, J. Kirby, M. Harris, A. Schmidt; WA- C. Kishiyama, C. Flores, J. Milton, W. Martin, C. Whysham, A. Yerka, T. Freels, J.M. Hassing, J. Webster; Springfield, IL- R. Green, P. Carter, J. Galloway, D. Hoelzer, S. Roberts, S. Said, P. Sullivan; Springfield, MA- H.F. Allen, E. Reiter, E. Feinberg, C. Johnson; St. John's, NL- L.A. Newhook, D. Hagerty; St. Louis, MO- N.H. White, L. Levandoski; St. Paul, MN- J. Kylo, M. Johnson, C. Benoit; St. Petersburg, FL- P. Iyer, F. Diamond, H. Hosono, S. Jackman, L. Barette, P. Jones; Syracuse, NY- I. Sills, S. Bzdick, J. Bulger, R. Weinstock; Taunton, UK- I. Douek, R. Andrews, G. Modgill, G. Gyorffy, L. Robin, N. Vaidya, S. Crouch, K. O'Brien, C. Thompson, N. Thorne; Toledo, OH- J. Blumer, J. Kalic, L. Klepek, J. Paulett, B. Rosolowski, J. Horner, M. Watkins; Topeka, KS- J.L Casey, K. Carpenter, C. Burns, J. Horton, C. Pritchard, D. Soetaert, A.G. Wynne; Torrance, CA- K. Kaiserman, M. Halvorson; Tucson, AZ- C. Chin, O.Y. Molina, C. Patel, R. Senguttuvan, M. Wheeler, O. Furet, C. Steuhm; Tulsa, OK- D.H Jolley, S. Goudeau, L. Chalmers, D. Greer; Vancouver, B.C- C. Panagiotopoulos, D.L. Metzger, D. Nguyen, M. Horowitz; Walnut Creek, CA- M.P. Christiansen, E. Glades, C. Morimoto, M. Macarewich, R. Norman, K. Patin, C. Vargas, A. Barbanica, A. Yu; Washington D.C- P. Vaidyanathan, W. Osborne, R. Mehra; Wenatchee, WA- S. Kaster, S. Neace, J. Horner; Wilmington, DE- G. Reeves, C. Cordrey, L. Marrs, T. Miller, S. Dowshen, D. Doyle; Winnipeg, Manitoba- S. Walker, D. Catte, H. Dean; Winston-Salem, NC- M. Drury-Brown, B. Hackman; Worcester, MA- M.M.C Lee, S. Malkani, K. Cullen, K. Johnson; Yuma, AZ- P. Hampton, M. McCarrell, C. Curtis, E. Paul, Y. Zambrano.